中国青年报客户端讯（中青报·中青网记者 林洁）12月27日，广药集团科技创新大会在广州举行。广药 集团宣布，"十五五"时期拟投入100亿元至150亿元研发费用，加大新药研发力度，打造科技创新型企 业，通过建立健全科技创新的容错机制，优化重大项目决策机制，以更大力度推进科技创新布局。 广药集团 七大创新平台获授旗。主办方供图 同时，广药集团将设立广药资本运营公司，加强资本运作，持续撬动社会资本扩容增效。"十五五"期间 预计研发投入100亿元至150亿元；产业投资与并购200亿元至300亿元，聚合创新生态。广药集团还将携 手大院大所共建高水平联合实验室和创新研究院，联动上下游企业，构建全产业链创新生态，提升科技 成果转化效能。 广药集团将整合科研体系资源，构建覆盖全产业链、面向未来的科研与转化支柱体系。广药集团已打造 以七大创新研发平台为核心的创新平台体系，包括中医药创新平台、化学药创新平台、生物药创新平 台、高端营养创新平台、核医药创新平台、动物保健创新平台、医疗器械创新平台。 当天，广药集团逾20个合作项目进行签约，包括在核医药、动物保健业务等新赛道加速布局。广药集团 拥有超200项在研项目，涵盖恶性肿瘤、慢 ...

Core Viewpoint - The new leadership of Guangzhou Pharmaceutical Group aims to lead the company out of a low operational period by focusing on technological innovation and transformation during the 14th Five-Year Plan period [3]. Group 1: Innovation Strategy - The company plans to invest between 10 billion to 15 billion yuan in research and development and 20 billion to 30 billion yuan in industrial investment and acquisitions during the 14th Five-Year Plan [3]. - The strategy includes building incubation platforms, aggregating innovation ecosystems, and enhancing talent acquisition and platform development to accelerate innovation transformation [3][6]. Group 2: Business Performance - Guangzhou Pharmaceutical Group's listed company, Baiyunshan, derives its revenue from three main sectors: traditional Chinese medicine, health products, and pharmaceutical distribution [3]. - The pharmaceutical distribution sector generated 29 billion yuan in revenue in the first half of 2025, accounting for nearly 70% of Baiyunshan's total revenue, but with a low gross margin of 6.13% [4]. - The health products sector followed with a revenue of 7.02 billion yuan and a gross margin of 44.67%, while the traditional Chinese medicine sector generated 5.24 billion yuan with a gross margin of 49.71% [4]. Group 3: Challenges and Market Dynamics - The health products and traditional Chinese medicine sectors are experiencing sluggish growth due to intense competition in the beverage industry and ongoing drug procurement policies [5]. - Traditional pharmaceutical companies that have prioritized innovation are seeing growth in sales of innovative drugs and external licensing, contrasting with the challenges faced by traditional Chinese medicine companies, which struggle with innovation capacity and aging product structures [5]. Group 4: Commitment to Innovation - Baiyunshan's R&D investment was only 828 million yuan in 2024, representing just 4.26% of the company's revenue, indicating a need for increased focus on innovation [6]. - The company is committed to a dual approach of self-research and acquisitions to drive innovation, aiming for results from acquisitions within one to two years and from self-research within five to ten years [6].

Core Viewpoint - The article discusses the urgent need for Guangzhou Pharmaceutical Group (广药集团) to innovate and transform in order to overcome its current operational challenges, with a focus on technology and research investment during the 14th Five-Year Plan period [3][4]. Group 1: Company Strategy and Goals - The company aims to invest between 10 billion to 15 billion yuan in research and development and 20 billion to 30 billion yuan in industrial investment and acquisitions during the 14th Five-Year Plan [3]. - The new management under Chairman Li Xiaojun emphasizes the importance of building an innovation ecosystem and a nurturing platform for talent [3][4]. Group 2: Current Business Performance - Guangzhou Pharmaceutical's listed subsidiary, Baiyunshan, derives most of its revenue from three main sectors: traditional Chinese medicine, health products, and pharmaceutical distribution [4]. - The pharmaceutical distribution sector is the largest revenue contributor, generating 29 billion yuan in the first half of 2025, accounting for nearly 70% of Baiyunshan's total revenue, but with a low gross margin of 6.13% [4]. - The health products sector generated 7.02 billion yuan with a gross margin of 44.67%, while the traditional Chinese medicine sector brought in 5.24 billion yuan with a gross margin of 49.71% [4]. Group 3: Challenges and Industry Context - The company faces challenges such as intense competition in the beverage industry and ongoing drug procurement policies, leading to sluggish growth in its health products and traditional medicine sectors [5]. - Compared to innovative pharmaceutical companies that have successfully increased revenue through innovative drug sales and licensing, Guangzhou Pharmaceutical's traditional focus on Chinese medicine has resulted in insufficient innovation capabilities and an aging product structure [5][6]. Group 4: Future Outlook and Innovation Focus - The company plans to adopt a dual approach of self-research and acquisitions to drive innovation, targeting best-in-class positions in specific fields [7]. - The management acknowledges the need for a long-term commitment to innovation, with expected results from acquisitions within one to two years and from self-research within five to ten years [7].

Core Viewpoint - Guangzhou Pharmaceutical Group is accelerating its innovation transformation to overcome operational challenges and aims to invest significantly in research and development as well as industry acquisitions during the 14th Five-Year Plan period [1][5]. Group 1: Innovation Strategy - The company plans to invest between 10 billion to 15 billion yuan in R&D and 20 billion to 30 billion yuan in industrial investments and acquisitions during the 14th Five-Year Plan [1]. - The management emphasizes the need for a dual approach of "self-research + acquisitions" to drive innovation in the pharmaceutical sector [5]. - The company aims to achieve best-in-class status in certain fields and is prepared for a long-term commitment to innovation despite the inherent risks and challenges [5]. Group 2: Business Performance - The major revenue source for Guangzhou Pharmaceutical's listed company platform, Baiyunshan, is the large commercial sector, which generated 29 billion yuan in revenue in the first half of 2025, accounting for nearly 70% of total revenue [2]. - The health sector follows with a revenue of 7.02 billion yuan and a gross margin of 44.67%, while the large pharmaceutical sector generated 5.24 billion yuan with a gross margin of 49.71% [2]. - The performance of the health and pharmaceutical sectors has been sluggish due to increasing competition in the beverage industry and ongoing drug procurement policies [4]. Group 3: Challenges and Market Dynamics - Traditional pharmaceutical companies that have successfully transitioned to innovation have seen growth in sales and licensing revenues, contrasting with traditional Chinese medicine companies facing challenges such as insufficient innovation capacity and aging product structures [5]. - Baiyunshan's R&D investment was only 828 million yuan in 2024, representing a low proportion of 4.26% of the company's revenue, indicating a need for increased focus on innovation [5].

科技创新是医药健康产业发展的核心引擎。12月27日，2025广药集团科技创新大会在广州召开，吹 响了打造医药健康创新型企业的奋进号角。本次大会以"创新转型 开放共赢"为主题，汇聚顶尖院士、 行业翘楚以及合作伙伴，共商医药健康产业创新大计，向世界传递广药集团"科技引领、创新引领"的发 展理念，聚力构建开放共赢的创新生态，以新质生产力擘画高质量发展新蓝图。 钟南山、饶子和、魏于全、马骏、张亚平、曾木圣、朱健康、周大旺等院士和全国医药健康领域的 专家学者齐聚大会，全国政协常委、湖南省政协副主席、教授张灼华，广州市副市长江智涛，广东省工 业和信息化厅党组成员陈绩以及广东省、广州市相关领导，广药集团合作伙伴，广药集团党委书记、董 事长李小军，党委副书记、副董事长、总经理陈杰辉等出席大会。 "十五五"广药集团打造科技创新型企业 人才与平台，是驱动科技创新的核心双翼。为赋能"十五五"期间产业跨越发展，大会期间，广药集 团还举行了科技委员会主任、战略专家顾问、首席专家顾问、资深专家顾问的聘任仪式，包括3名院士 在内的超30名专家为广药集团"科技创新大脑"赋能，助力集团建设一个创新动能更澎湃的科技新高地。 拟投入研发费用100 ...

Core Insights - The Guangzhou Pharmaceutical Group is accelerating its transformation into a technology-driven and innovative enterprise, with a focus on modernization, digitalization, technological advancement, and internationalization during the 14th Five-Year Plan period [2][3] Investment and Innovation Strategy - The company plans to invest between 100-150 billion yuan in research and development and 200-300 billion yuan in industrial investment and acquisitions during the 14th Five-Year Plan [3][4] - The strategy includes building incubation platforms, enhancing innovation ecosystems, and optimizing incentives to achieve the goal of becoming a world-class pharmaceutical and health technology innovation enterprise [3][4] Expert Collaboration - Over 30 experts, including three academicians, have been appointed to form an advisory "brain" for the company's innovation efforts, emphasizing the importance of scientific insight and advanced technology platforms in modern pharmaceutical innovation [4][6] Innovation Platforms - The company has established seven major innovation platforms, including Traditional Chinese Medicine, chemical drugs, biological drugs, high-end nutrition, nuclear medicine, animal health, and medical devices, to strengthen its innovation capabilities [8] - The platforms aim to facilitate the transition from laboratory research to production, addressing the "last mile" challenge in drug development [8] Strategic Partnerships - More than 20 cooperation projects were signed at the conference, including strategic collaborations with Muen Bio, Data Science Group, Huawei Technologies, and various universities to enhance digital development and promote the application of microbiological technologies [9]

中新网广州12月27日电 (记者 蔡敏婕)2025广药集团科技创新大会27日在广州举行。钟南山、饶子和、 魏于全、马骏、张亚平、曾木圣、朱健康、周大旺等院士和全国医药健康领域的专家学者齐聚大会。 中国科学院院士饶子和表示，现代医药创新的竞争正日益成为源头科学洞察与尖端技术平台的双重竞 争。企业的创新不能再局限于开发环节，必须具备向科学源头追溯的勇气与能力。 活动期间，多位院士、专家还围绕生物技术助力健康长寿、肿瘤靶向治疗、先进治疗药品、学科交叉推 动药物创新、以临床问题为导向开展科技创新等前沿议题开展主题演讲。 此外，中药制药过程技术与新药创制国家工程研究中心藏药综合开发创新联合体、广药集团生物医药产 业研究院、广药集团前沿生物技术创新中心、广州医药数智科技公司、甘肃省中药发酵工程(合成生物) 研究中心、医用同位素和放射性药物先进创新中心(广州)等重要创新平台在会上揭牌。(完) 院院士钟南山出席大会。主办方 供图 "当前中国医药产业正处于从'仿制跟随'走向'源头创新'、从'规模扩张'转向'价值创造'的关键节点。"中 国工程院院士钟南山表示，中医药创新发展离不开良好的生态环境。只有构建让科研人员敢于瞄准难题 潜 ...

每经AI快讯，12月27日，据广药白云山消息，在2025广药集团科技创新大会上，广药集团党委副书 记、副董事长、总经理陈杰辉作科技创新转型报告，他表示，广药集团将搭建孵化平台、聚合创新生 态，"十五五"期间预计完成研发投入100亿元-150亿元、产业投资与并购200亿元-300亿元，并通过举才 引智、建强平台、深耕生态、拓展布局、优化激励等途径，全速推进创新转型。 ...

Core Viewpoint - During the 15th Five-Year Plan period, Guangzhou Pharmaceutical Group plans to invest approximately 10 billion to 15 billion yuan in R&D and allocate about 20 billion to 30 billion yuan for industrial investment and mergers and acquisitions to promote innovation and transformation [1] Group 1: Strategic Collaborations - Guangzhou Pharmaceutical Group has established a strategic partnership with Muen Bio to advance the industrial application of microbiological technologies [1] - Collaborations have been initiated with Digital Science Group and Huawei Technologies to enhance the information management level of drug safety through the "Drug Vigilance Intelligent Management System" project [1] - Partnerships have been formed with Central South University, Capton Company, and others to promote collaborative efforts in production, education, and research [1] Group 2: New Business Directions - Collaborations with the Guangzhou Development Zone Management Committee and various hospitals aim to advance the full industrial chain development of nuclear medicine [1] - Guangzhou Animal Health Technology Company has signed agreements with various pet hospital management companies to expand into the animal health business [1] - The Fruit Tree Science Research Institute has signed a cooperation agreement with Zhanjiang Agricultural Reclamation Science Research Institute to conduct trials on new variety facility cultivation [1] Group 3: Capital Operations - Guangzhou Capital is engaging in partnerships with multiple companies to accelerate capital operations and expand its industrial footprint [1]

Core Viewpoint - The opening of the "Farm Garden Feast" fresh vegetable hotpot restaurant in Guangzhou represents a significant upgrade and transformation of a 30-year-old dining brand, focusing on green, healthy, and fashionable dining experiences while promoting local agricultural products [4][10][11]. Group 1: Restaurant Overview - The "Farm Garden Feast" restaurant officially opened on December 26, 2023, and is a rebranding of a hotpot restaurant established in 1993 by the Guangzhou Vegetable Science Research Institute [4][9]. - The restaurant emphasizes the use of high-quality free-range ecological chicken and specialty vegetables, aiming to bridge the gap between agricultural brands and consumers [11][12]. - The restaurant serves as a platform for showcasing unique agricultural products and aims to connect farm produce directly to consumers [15][16]. Group 2: Strategic Partnerships and Goals - The restaurant's opening was attended by representatives from various agricultural and health organizations, indicating strong support from the local agricultural sector [5][7]. - The establishment of the restaurant is part of a broader strategy by Guangzhou Pharmaceutical Group to deepen its involvement in the agricultural sector and the health industry [21][22]. - The restaurant aims to enhance food safety, strengthen brand building, and improve the dining experience for consumers [23][25]. Group 3: Supply Chain and Product Sourcing - All ingredients used in the restaurant are sourced from standardized planting demonstration bases, ensuring traceability from farm to table [30][32]. - The restaurant collaborates with several authoritative institutions to ensure high-quality agricultural products are offered, showcasing over 30 types of specialty vegetables at its opening [29][31]. - The initiative is part of a commitment to innovate and integrate agriculture with the dining industry, aiming to create a significant agricultural technology brand [36][38].